[Clinical development of anti-FXII therapeutics as a target in thrombo-inflammation].

Autor: Munoz T; Hematology Department, Assistance Publique Hôpitaux de Paris.Centre-Université Paris Cité (APHP.CUP), 75015 Paris, France., Bentounes NK; Hematology Department, Assistance Publique Hôpitaux de Paris.Centre-Université Paris Cité (APHP.CUP), 75015 Paris, France., Melicine S; Hematology Department, Assistance Publique Hôpitaux de Paris.Centre-Université Paris Cité (APHP.CUP), 75015 Paris, France., Smadja DM; Hematology Department, Assistance Publique Hôpitaux de Paris.Centre-Université Paris Cité (APHP.CUP), 75015 Paris, France; Inserm, Innovative Therapies in Haemostasis, Paris-Cité University, 75006 Paris, France; INNOVTE, F-CRIN, Saint-Étienne, France., Gendron N; Hematology Department, Assistance Publique Hôpitaux de Paris.Centre-Université Paris Cité (APHP.CUP), 75015 Paris, France; Inserm, Innovative Therapies in Haemostasis, Paris-Cité University, 75006 Paris, France; INNOVTE, F-CRIN, Saint-Étienne, France. Electronic address: nicolas.gendron@aphp.fr.
Jazyk: francouzština
Zdroj: La Revue de medecine interne [Rev Med Interne] 2024 Aug; Vol. 45 (8), pp. 474-478. Date of Electronic Publication: 2024 Jun 06.
DOI: 10.1016/j.revmed.2024.03.012
Abstrakt: The history of anticoagulation has evolved considerably, from non-specific drugs to molecules that directly target specific coagulation factors, such as direct oral anticoagulants (DOACs). Since last decade, DOACs are widely used in clinical practice because of their ease to use with favorable pharmacological profile and not requiring monitoring. New therapeutics targeting the contact phase of coagulation are currently under development, and could make it possible to prevent thrombotic risk without altering hemostasis, thereby reducing the risk of bleeding. Factor XII, being at the crossroads between hemostasis and inflammation, appears to be an interesting target that could limit thrombo-inflammation without increasing bleeding risk. The aim of this article is to summarize the main information concerning FXII inhibitors and to review the results of various clinical trials available to date, focusing on applications beyond hemostasis, such as in the management of hereditary angioedema.
(Copyright © 2024 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: